Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
A Trial to Assess the Effect of Liraglutide on Blood Triglyceride (Fat) Levels After a Meal in Type 2 Diabetics
Phase 1
Completed
- Conditions
- Diabetes Mellitus, Type 2Diabetes
- Interventions
- Drug: placebo
- First Posted Date
- 2009-10-12
- Last Posted Date
- 2017-01-26
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 20
- Registration Number
- NCT00993304
- Locations
- 🇩🇰
Novo Nordisk Investigational Site, Aarhus C, Denmark
Comparison of the Effect of NN5401 With the Effect of NN1250 and Insulin Aspart in Type 1 Diabetics
Phase 1
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1
- Interventions
- First Posted Date
- 2009-10-09
- Last Posted Date
- 2013-11-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 27
- Registration Number
- NCT00992537
Investigation of the Response Relationship of NN5401 in Type 1 Diabetics
Phase 1
Completed
- Conditions
- Diabetes Mellitus, Type 1Diabetes
- Interventions
- First Posted Date
- 2009-10-09
- Last Posted Date
- 2017-02-10
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 33
- Registration Number
- NCT00993096
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany
Safety and Efficacy of Turoctocog Alfa (N8) in Prevention and On-demand Treatment of Bleeding Episodes in Subjects With Haemophilia A: An Extension to Trials NN7008-3543, NN7008-3545, NN7008-3600, NN7008-3893 and NN7008-4015
Phase 3
Completed
- Conditions
- Congenital Bleeding DisorderHaemophilia A
- Interventions
- First Posted Date
- 2009-09-25
- Last Posted Date
- 2017-07-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 214
- Registration Number
- NCT00984126
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Manchester, United Kingdom
Comparison of NN1250 Plus Insulin Aspart With Insulin Glargine Plus Insulin Aspart in Type 1 Diabetes
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1
- Interventions
- First Posted Date
- 2009-09-23
- Last Posted Date
- 2017-04-06
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 629
- Registration Number
- NCT00982228
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Sheffield, United Kingdom
Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2009-09-23
- Last Posted Date
- 2017-02-09
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1030
- Registration Number
- NCT00982644
- Locations
- 🇪🇸
Novo Nordisk Investigational Site, Valencia, Spain
Safety and Tolerability of NN9068 in Healthy Male Volunteers
Phase 1
Completed
- Conditions
- DiabetesHealthy
- Interventions
- First Posted Date
- 2009-09-23
- Last Posted Date
- 2017-02-08
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 24
- Registration Number
- NCT00983021
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany
Comparison of NN5401 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1
- Interventions
- First Posted Date
- 2009-09-17
- Last Posted Date
- 2017-03-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 548
- Registration Number
- NCT00978627
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Wirral, Merseyside, United Kingdom
A Trial to Assess the Effect of Liraglutide on Gastric Emptying in Healthy Obese Volunteers
- First Posted Date
- 2009-09-16
- Last Posted Date
- 2017-07-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 49
- Registration Number
- NCT00978393
- Locations
- 🇳🇱
Novo Nordisk Investigational Site, Maastricht, Netherlands
Safety of Monthly Recombinant Factor XIII Replacement Therapy in Subjects With Congenital Factor XIII Deficiency: An Extension to Trial F13CD-1725
Phase 3
Completed
- Conditions
- Congenital Bleeding DisorderCongenital FXIII Deficiency
- Interventions
- First Posted Date
- 2009-09-16
- Last Posted Date
- 2018-01-24
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 63
- Registration Number
- NCT00978380
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Newcastle upon Tyne, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath